Kane Biotech Inc.
KNBIF
$0.02
$0.0019.76%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -81.67% | 304.61% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -81.67% | 304.61% | |||
| Cost of Revenue | -86.14% | 264.56% | |||
| Gross Profit | 135.71% | -151.85% | |||
| SG&A Expenses | 42.81% | -11.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.33% | 18.06% | |||
| Operating Income | -14.09% | -7.24% | |||
| Income Before Tax | -14.34% | -8.79% | |||
| Income Tax Expenses | -10.00% | 103.87% | |||
| Earnings from Continuing Operations | -14.20% | -31.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.20% | -31.02% | |||
| EBIT | -14.09% | -7.24% | |||
| EBITDA | -15.45% | -6.81% | |||
| EPS Basic | -150.00% | -27.27% | |||
| Normalized Basic EPS | -144.44% | -12.50% | |||
| EPS Diluted | -150.00% | 33.33% | |||
| Normalized Diluted EPS | -144.44% | -12.50% | |||
| Average Basic Shares Outstanding | -54.16% | 0.14% | |||
| Average Diluted Shares Outstanding | -54.16% | 0.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||